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ABSTRACT: Multidrug membrane transporters can extrude a wide range of
substrates, which cause multidrug resistance and ineﬀective treatment of diseases. In
this study, we used three diﬀerent sized antibiotic drug nanocarriers to study their
size-dependent inhibitory eﬀects against Bacillus subtilis. We functionalized 2.4 ± 0.7,
13.0 ± 3.1, and 92.6 ± 4.4 nm silver nanoparticles (Ag NPs) with a monolayer of 11amino-1-undecanethiol and covalently linked them with antibiotics (oﬂoxacin, Oﬂx).
The labeling ratios of antibiotics with NPs are 8.6 × 102, 9.4 × 103, and 6.5 × 105 Oﬂx
molecules per NP, respectively. We designed cell culture medium in which both
BmrA and ΔBmrA cells grew and functioned normally while ensuring the stabilities of
nanocarriers (nonaggregation). These approaches allow us to quantitatively study the
dependence of their inhibitory eﬀect against two isogenic strains of B. subtilis, WT
(normal expression of BmrA) and ΔBmrA (deletion of bmrA), upon the NP size,
antibiotic dose, and BmrA expression. Our results show that the inhibitory eﬀects of
nanocarriers highly depend on NP size and antibiotic dose. The same amount of Oﬂx on 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm
nanocarriers shows the 3× lower, nearly the same, and 10× higher inhibitory eﬀects than that of free Oﬂx, against both WT and
ΔBmrA, respectively. Control experiments of the respective sized AgMUNH2 NPs (absence of Oﬂx) show insigniﬁcant inhibitory
eﬀects toward both strains. Taken together, the results show multiple factors, such as labeling ratios, multivalent eﬀects, and
pharmacodynamics (Oﬂx localization and distribution), which might play the roles in the size-dependent inhibitory eﬀects on the
growth of both WT and ΔBmrA strains. Interestingly, the inhibitory eﬀects of nanocarriers are independent of the expression of
BmrA, which could be attributed to the higher eﬄux of nanocarriers by other membrane transporters in both strains.

■

subtilis.23−25 BmrA (YvcC), the ABC transporter of B. subtilis,
exhibits the highest homology to each half of P-gps (MDR1),
HorA (40% identity), and LmrA (42% identity), which makes
it an excellent choice to study multidrug ABC transporters.26
Fluoroquinolones (e.g., Oﬂx, norﬂoxacin, ciproﬂoxacin, levoﬂoxacin, and gemiﬂoxacin) are widely used antibiotics to treat
a variety of respiratory and urinary tract infections, which
include pneumonia, chronic bronchitis, and tuberculosis.27,28
The extensive use of conventional antibiotics has led to the
development of multiantibiotics resistance and the creation of
superbugs that cannot be eﬀectively eradicated by traditional
antibiotics; hence, there is an urgent need to design new types
of antibiotics and unconventional drugs (e.g., nanomedicine)
to treat the infections.
Noble metal nanoparticles (NPs) possess unique physicochemical properties. Their high surface-area-to-volume ratio

INTRODUCTION
ATP-binding cassette (ABC) membrane transporters are one
of the largest membrane transport superfamilies, and they exist
in all living organisms and play highly signiﬁcant roles in
biological functions.1−7 The ABC membrane transporters can
selectively transport a wide variety of substrates across cellular
membranes, even though they share a common modular
architecture, two transmembrane domains (TMDs) and two
nucleotide-binding domains (NBDs). TMDs exhibit variable
sequence and topology and deﬁne substrate binding sites and
transport passageway, while the NBDs possess conserved
sequences and bind and hydrolyze ATP to provide the “powerstroke” for the transporters to translocate the speciﬁc
substrates across the cellular membrane.7−17 The multidrug
ABC membrane transporters can extrude chemotherapeutic
agents out of bacteria or tumor cells, which causes multidrug
resistance (MDR) and ineﬀective treatment of diseases,
underscoring the importance of understanding their underlying
mechanisms to design more eﬀective therapy.3,18−22
Bacillus subtilis (a Gram-positive bacterium) is a widely used
model organism to study multidrug ABC transporters. Current
studies show that there are 78 ABC transporters in B.
© 2020 American Chemical Society
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Figure 1. Chemical reactions for the preparation of antibiotic drug nanocarriers (AgMUNH−Oﬂx NPs): attaching monolayer of 11-amino-1undecanethiol onto the surface of (A) 2.4 ± 0.7, (B) 13.0 ± 3.1, and (C) 92.6 ± 4.4 nm NPs to prepare AgMUNH2 NPs and then linking the
amine group of 11-amino-1-undecanethiol with the carboxyl group of the Oﬂx via peptide bonds using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and sulfo-N-hydroxysulfosuccinimide (NHS) as mediators to generate AgMUNH−Oﬂx NPs (antibiotic drug
nanocarriers).30

highly depends upon the NP size, antibiotic dose, and
multidrug membrane transporter (MexAB-OprM) expression.
In this study, we used the same nanocarriers to study the
dependence of inhibitory eﬀect of the antibiotic nanocarriers
against Gram-positive bacteria, two strains of B. subtilis (Grampositive bacteria), WT (normal expression of BmrA) and
ΔBmrA (deletion of bmrA), upon the size of nanocarriers, and
dose of antibiotics (Oﬂx). Note that MexAB-OprM and BmrA
are two completely diﬀerent types of multidrug membrane
transporters, energized by proton gradients across the cellular
membrane and ATP hydrolysis, respectively. Further, P.
aeruginosa are Gram-negative bacteria, while B. subtilis are
Gram-positive bacteria, and they have very diﬀerent cellular
envelop structures. By comparing these two studies, we aim to
understand the dependence of inhibitory eﬀects of nanocarriers upon the types of multidrug membrane transporters
and the types of bacteria.

allows them to serve as eﬀective drug carriers that oﬀer high
payloads, high permeability, high local target concentrations,
and high binding aﬃnity due to multivalence eﬀects.29−31
Furthermore, the high surface-area-to-volume ratio of NPs
could also lead to high chemical reactivity, and bare NPs
themselves could serve as unconventional drugs to eradicate
bacteria.29,31−33 In our previous studies, we found that Ag and
Au NPs at low concentrations do not inhibit cell growth and
are biocompatible, while a higher concentration of NPs was
unstable in the buﬀer or medium, which led to the aggregation
of bare NPs on the surface of the cellular membrane that
causes cell death.30,32−40
We have successfully imaged single Ag NPs in solution, in
single live cells, and single embryos and used their sizedependent plasmonic optical properties to study size-dependent eﬄux functions of multidrug membrane transporters in
single live cells (both Gram-positive and Gram-negative
bacteria) in real time at nanometer resolution.33−36,38−51 We
have also used their size-dependent plasmonic optical properties to characterize the mode of action of antibiotics, such as
aztreonam and chloramphenicol, in single live Pseudomonas
aeruginosa cells.37,40 Therefore, the plasmonic NP-based drug
carriers can serve as size-dependent photostable-sized imaging
probes to study size-dependent eﬄux kinetics of multidrug
membrane transporters and size-dependent MDR in situ in real
time, while nanocarriers are inhibiting the bacterial growth.
In our previous study, we have designed, synthesized,
puriﬁed, and characterized three diﬀerent sized antibiotic
nanocarriers and developed cell culture medium, in which P.
aeruginosa (Gram-negative bacteria) cells grew and functioned
normally and the nanocarriers remained unchanged (stable,
nonaggregated).30 We found that their inhibitory eﬀect against
two strains of P. aeruginosa, WT (normal expression of
MexAB-OprM) and ΔABM (deletion of MexAB-OprM),

■

RESULTS AND DISCUSSION
Synthesis, Puriﬁcation, and Characterization of
Stable Drug Nanocarriers. We synthesized, puriﬁed, and
characterized 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm Ag NPs.
We used the thiol group of 11-amino-1-undecanethiol
hydrochloride (AUT) to attach a monolayer of AUT
(MUNH2) onto surface of NPs to prepare AgMUNH2 NPs
(Figure 1), as reported previously.30 We then used a peptide
bond to covalently conjugate the carboxyl group of Oﬂx with
the amine group of AgMUNH2 NPs to synthesize antibiotic
drug nanocarriers (AgMUNH−Oﬂx) (Figure 1).30
We puriﬁed the drug nanocarriers using centrifugation. We
then characterized the sizes of the NPs, AUT (MUNH2) on
the NPs, and conjugation ratios of Oﬂx molecules per NP for
2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm NPs as 8.6 × 102, 9.4
× 103, and 6.5 × 105 using transmission electron microscopy
1626
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We then used live/dead BacLight assay to determine the
viability of the cells, which had been cultured in the standard
and modiﬁed media over 17 h. For live/dead BacLight assay,52
green ﬂuorescent dye (SYTO9, λmax = 520 nm) stains only live
cells, while a red ﬂuorescent dye (propidium iodide, λmax = 610
nm) can only diﬀuse into the dead cells because of
disintegrated cellular membranes of dead cells. Thus, the live
cells exhibit green ﬂuorescent, while dead cells display red
ﬂuorescent. The results in Figure 3 show that more than 97%

and dynamic light scattering (DLS), NMR, and UV−vis
spectroscopy, respectively.30
We used DLS and UV−vis spectroscopy to study the
stability (nonaggregation) of antibiotic drug nanocarriers with
desired concentrations in a commonly used standard Lysogeny
broth (LB) medium (1% tryptone, 0.5% yeast extract, and
0.5% NaCl in deionized (DI) water, pH = 7.2) in the shaker
(MaxQ 5000, 200 rpm, 37 °C) for 12 h. We found that they
were aggregated.30 The aggregation of nanocarriers would alter
their sizes and cause potential precipitation of nanocarriers
from the medium that would reduce their doses and make the
study of dose- and size-dependent unreliable. Therefore, we
modiﬁed the cell culture medium by reducing the NaCl
concentration from 0.5 to 0.1% and found that the drug
nanocarriers with desired concentrations in the modiﬁed LB
medium (1% tryptone, 0.5% yeast extract, and 0.1% NaCl in
DI water, pH = 7.2) were stable (nonaggregated) under the
cell culture condition and duration, in the shaker (MaxQ 5000,
200 rpm, 37 °C) for 12 h.
Characterization of Cellular Functions in the Modiﬁed Medium. We characterized the viability and eﬄux
function of the cells cultured in the modiﬁed medium to make
certain that the modiﬁed cell culture medium can be used to
culture healthy and well-functional cells as those cultured in
the standard cell culture medium. We precultured the cells
(WT-BmrA and ΔBmrA) in the standard medium for 12 h,
then cultured the precultured cells in the standard medium and
the modiﬁed medium, and followed the cell growth over time.
The growth curves of the cells cultured in the standard
medium (Figure 2a) and the modiﬁed medium (Figure 2b) for
WT (Figure 2A) and ΔBmrA (Figure 2B) are the same,
showing that the cells grow normally in the modiﬁed cell
culture medium.

Figure 3. Study of the viability of the cells (WT and ΔBmrA)
cultured in (a) standard and (b) modiﬁed LB medium using live/dead
BacLight assay. (A) Optical and (B) ﬂuorescence images of the cells
(e.g., WT) that were cultured over 12 h and suspended in the
phosphate-buﬀered saline (PBS) buﬀer and assayed using live/dead
BacLight assay. The cells exhibiting green ﬂuorescence and red
ﬂuorescence are counted as live and dead cells, respectively. (C) Plot
of the percent of the live cells (number of live cells divided by the
total number of the cells) cultured in (a) standard and (b) modiﬁed
LB media shows that more than 97% of the cells (WT and ΔBmrA)
are viable, which further demonstrates that the modiﬁed LB medium
can be used to culture the cells. The scale bar is 5 μm.

of the cells cultured in both media over time exhibit SYTO9
green ﬂuorescence, which demonstrates that 97% of the cells
are viable. The results further demonstrate that the cells
(BmrA and ΔBmrA) cultured in the modiﬁed medium grow
normally and they are viable.
To characterize the eﬄux function of multidrug BmrA
transporters of live cells, we studied the BmrA-dependent
eﬄux kinetics of intracellular Hoechst dye (Hoechst 33342) in
both WT and ΔBmrA live cells using ﬂuorescence spectroscopy.39,51,53−57 Hoechst dye molecules emit weak ﬂuorescent
outside the cells, and their ﬂuorescence intensity increases up
to 10-folders as they enter the cells and intercalate with
DNA.26,58 Thus, the time course ﬂuorescence intensity of the
dyes can be used to study their accumulation kinetics inside
live cells in real time. The ﬂuorescence intensity of the dyes
incubated with ΔBmrA (absence of BmrA) increases with time
more rapidly (Figure 4b) than those of WT (Figure 4a),
showing that the eﬄux of the dye molecules out of the WT
cells leads to a lower accumulation of intracellular dye

Figure 2. Study of the suitability of the modiﬁed LB medium to
culture (A) WT and ΔBmrA: the cellular growth curves of (A) WT
and (B) ΔBmrA cultured in (a) standard and (b) modiﬁed LB media
over time show that the growth rates of a given strain in either
medium are nearly identical, which indicates that the modiﬁed LB
medium can be used to culture both WT and ΔBmrA cells.
1627
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Figure 5. Study of the dependence of inhibitory eﬀects of antibiotic
nanocarriers (AgMUNH−Oﬂx NPs) against the growth of (A−D)
WT and (E−H) ΔBmrA cells upon antibiotic dose, NP size, and
BmrA expression. Photographs of the LB medium cultured with (A−
D) the WT cells and (E−H) ΔBmrA containing (a−f) 0, 0.055, 0.11,
0.22, 0.42, and 0.72 μM of (A and E) unconjugated free Oﬂx alone;
(a−f) 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μM of the Oﬂx conjugated
with the Ag NPs of (B and F) 2.4 ± 0.7, (C and G) 13.0 ± 3.1, and
(D and H) 92.6 ± 4.4 nm in diameters, respectively. The
concentrations of Oﬂx conjugated onto the NPs are determined
using their labeling ratios. The blank control experiments include the
concentrations of AgMUNH2 NPs in (a) of (B−D and F−H)
containing 0.83 nM, 7.6 × 10−2 nM, or 1.1 pM AgMUNH2 NPs (in
the absence of Oﬂx) for 2.4 ± 0.7, 13.0 ± 3.1, or 92.6 ± 4.4 nm NPs,
which are the same concentrations of the NPs of nanocarriers as those
in (f) for each type of NPs (B−D and F−H), respectively.

Figure 4. Characterization of the eﬄux function of membrane
transporter (BmrA) in WT and ΔBmrA cells cultured in (A) standard
and (B) modiﬁed LB medium. Time-dependent ﬂuorescence intensity
of 2 μM Hoechst dye incubated with the cells (OD600 nm = 0.1 in PBS
buﬀer, pH 7.2): (a) WT and (b) ΔBmrA cultured in (A) standard
and (B) modiﬁed LB media show nearly identical accumulation and
eﬄux kinetics, demonstrating that the cells cultured in the modiﬁed
LB medium possess well-functional eﬄux pump and the modiﬁed LB
medium can be used to culture the cells for the study of accumulation
and eﬄux kinetics of B. subtilis.

molecules in the WT than in ΔBmrA cells. The results show
the high BmrA-dependent eﬄux kinetics of intracellular dye in
live cells that were cultured in both standard and modiﬁed cell
culture media (Figure 4A,B), respectively. The eﬄux kinetics
of cells cultured in the standard medium (Figure 4A) are
similar to those cells cultured in the modiﬁed medium, further
demonstrating that the modiﬁed cell culture medium is well
suitable to culture WT and ΔBmrA cells that preserve the
eﬄux function of multidrug BmrA membrane transporters.
Study of Antibiotic Dose, NP Size, and BmrA
Expression-Dependent Inhibitory Eﬀects. We measured
minimal inhibitory concentration (MIC) of Oﬂx attached onto
the nanocarriers to determine whether inhibitory eﬀects of
antibiotic nanocarriers against the growth of WT-BmrA and
ΔBmrA depend on the NP size, Oﬂx dose, and BmrA
expression. The cells (WT or ΔBmrA) were cultured in the
modiﬁed LB medium containing a dilution series of free Oﬂx
alone, each type of the given sized drug nanocarriers
(AgMUNH−Oﬂx NPs) and AgMUNH2 NPs (absence of
Oﬂx, control experiment), and the cell growth was measured
over time.
The dilution series contains 0, 0.055, 0.11, 0.22, 0.42, and
0.72 μM of free Oﬂx (Figure 5A,E) or Oﬂx carried by the NPs
(AgMUNH−Oﬂx NPs) for WT-BmrA (Figure 5B−D) and
ΔBmrA (Figure 5F−H), respectively. The corresponding
concentrations of nanocarriers (NP concentration) are (Figure
5B: a−f) 0, 0.06, 0.13, 0.26, 0.49, and 0.83 nM for (2.4 ± 0.7)
nm NPs with a conjugation ratio of 8.6 × 102 Oﬂx molecules
per NP; (Figure 5C: a−f) 0, 5.8 × 10−3, 1.2 × 10−2, 2.3 × 10−2,

4.5 × 10−2, and 7.6 × 10−2 nM for (13.0 ± 3.1) nm NPs with a
conjugation ratio of 9.4 × 103 Oﬂx molecules per NP; (Figure
5D: a−f) 0, 8.4 × 10−5, 1.7 × 10−4, 3.4 × 10−4, 6.4 × 10−4, and
1.1 × 10−3 nM for (92.6 ± 4.4) nm NPs with a conjugation
ratio of 6.5 × 105 Oﬂx molecules per NP, respectively. The
control experiments include the cells cultured with the LB
medium alone (blank control, Figure 5A,E: a) or the medium
containing 0.83, 7.6 × 10−2, or 1.1 × 10−3 nM AgMUNH2 NPs
(in the absence of Oﬂx, Figure 5B−H: a) for the (2.4 ± 0.7),
(13.0 ± 3.1), or (92.6 ± 4.4) nm NPs, respectively. The
control experiments were conducted in parallel with the
experiments with antibiotic nanocarriers and at the same
conditions.
We quantitatively measured the cell concentration over time
by measuring their OD600 nm (optical density at 600 nm) at 5,
11, and 17 h, as shown in Figures S1 and S2 in the Electronic
Online Supporting Information. Since nanocarriers and NPs
possess plasmonic optical properties and molecular absorption
at visible wavelengths, we subtracted the OD600 nm of the
nanocarriers or AgMUNH2 NPs in the medium (in the
absence of the cells) from the OD600 nm of the cell suspension
with the nanocarriers or NPs to determine the cell
concentration, respectively. The subtracted OD600 nm of the
cell suspension was plotted over time to determine the
duration (17 h) for the cell growth to reach equilibrium. The
OD600 nm of the cell suspension at 17 h was then plotted versus
1628
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the surface molecules, instead of the bare NPs.41,45,61 Thus, the
biocompatibility of AgMUNH2 NPs that we observed in the
study is most likely attributed to the surface functional
molecules (MUNH2) that are attached on the surface of the
NPs.
On the contrary, the OD600 nm of the cell suspension
incubated with Oﬂx alone or Oﬂx attached onto the given sized
nanocarriers decrease as Oﬂx concentration increases, showing
that their inhibitory eﬀects against the growth of WT and
ΔBmrA cells highly depend upon the dose of Oﬂx and size of
nanocarriers (Figure 6A,B: d−f). We ﬁtted the experimental
data with an exponential decay equation (y = a e−bx), which
represents the inhibitory eﬀect upon the exponential cell
growth. We deﬁne the concentration of Oﬂx needed to reduce
the growth of the cells in the medium alone to the half as the
MIC of Oﬂx. The results of MICs are summarized in Table 1,

the concentration of Oﬂx alone or Oﬂx covalently conjugated
with a given sized antibiotic drug nanocarrier to determine the
MIC of Oﬂx for each cell strain (Figure 6). The result shows
that the inhibitory eﬀects of Oﬂx highly depend on the dose of
Oﬂx and size of the nanocarriers but not on the cellular
expression of BmrA.

Table 1. Study of Dependence of MIC of Oﬂx upon the Size
of Nanocarriers and Expression of BmrA of Two Strains of
B. subtilis (WT and ΔBmrA)
MIC50 of Oﬂx (μM)a
samples

WT

ΔBmrA

free Oﬂx alone
nanocarriers (2.4 ± 0.7 nm)
nanocarriers (13.0 ± 3.1 nm)
nanocarriers (92.6 ± 4.4 nm)

0.16 ± 0.00
0.40 ± 0.02
0.12 ± 0.01
0.012 ± 0.001

0.17 ± 0.02
0.49 ± 0.03
0.11 ± 0.01
0.012 ± 0.001

The experimental data was ﬁtted using the exponential decay
equation (y = a e−bx) to determine the parameters (a and b) with the
highest regression. The MIC of Oﬂx for each sample was determined
at the half of the cell growth of the blank control experiment (Figure
6).
a

Figure 6. Study of dose-, size-, and BmrA-dependent MICs of
antibiotic nanocarriers (AgMUNH−Oﬂx NPs) against (A) WT and
(B) ΔBmrA cells. Plots of normalized OD600 nm of the cells cultured
for 17 h in the modiﬁed LB medium containing (a−c) AgMUNH2
NPs (absence of Oﬂx, control), (d) Oﬂx alone, and (e−g) Oﬂx linked
with (e) 2.4 ± 0.7, (f) 13.0 ± 3.1, and (g) 92.6 ± 4.4 nm Ag NPs,
respectively. The concentrations of AgMUNH2 NPs in (a−c) of (A)
and (B) are the same as the given sized nanocarriers with the highest
Oﬂx concentrations in (e−g) for each type of NPs in (A) and (B), but
without Oﬂx (control experiments for the study of eﬀects of NPs),
respectively. The experimental data (points) are ﬁtted with an
equation y = a e−bx, solid line as follows: (A): (d) y = 1.12 e−5.02×, R2 =
0.918; (e) y = 1.10 e−1.964×, R2 = 0.841; (f) y = 1.11 e−6.53×, R2 = 0.881;
(g) y = 1.00 e−55.48×, R2 = 1.000. (B): (d) y = 1.12 e−4.55×, R2 = 0.922;
(e) y = 1.10 e−1.59×, R2 = 0.712; (f) y = 1.09 e−7.09×, R2 = 0.906; (g) y =
1.00 e−52.01×, R2 = 1.000. The MICs (IC50) of free Oﬂx and linked
Oﬂx were determined at the half of the maximum of the normalized
OD600 nm for each curve (solid line).

showing that the MICs of free Oﬂx and Oﬂx attached onto the
nanocarriers highly depend upon the dose of Oﬂx and the size
of nanocarriers but not the cellular expression of BmrA.
For free Oﬂx alone (Figure 6A,B: d), the OD600 nm of the cell
suspension decrease with the Oﬂx concentration, showing the
MICs of 0.16 ± 0.00 and 0.17 ± 0.02 μM Oﬂx for the WT and
ΔBmrA cells, respectively.
Interestingly, for 2.4 ± 0.7 nm drug nanocarriers with a
conjugation ratio of 8.6 × 102 Oﬂx molecules/NP (Figure
6A,B: e), the OD600 nm of the cell suspension decrease with the
Oﬂx concentration less rapidly than those of free Oﬂx and two
other larger nanocarriers. Notably, for 13.0 ± 3.1 nm drug
nanocarriers with a conjugation ratio of 9.4 × 103 Oﬂx
molecules/NP (Figure 6A,B: f), the OD600 nm of the cell
suspension decreases with the Oﬂx concentration are nearly
the same as those of free Oﬂx, showing the nearly identical
inhibitory and MICs of 0.12 ± 0.01 and 0.11 ± 0.01 μM Oﬂx
for the WT and ΔBmrA cells, as those of free Oﬂx,
respectively. For 92.6 ± 4.4 nm drug nanocarriers with a
conjugation ratio of 6.5 × 105 Oﬂx molecules/NP (Figure
6A,B: g), the OD600 nm of the cell suspension decrease with the
Oﬂx concentration the most rapidly, showing the highest
inhibitory eﬀects and the lowest MICs of 0.012 ± 0.001 and
0.012 ± 0.001 μM Oﬂx for the WT and ΔBmrA cells,
respectively.
The MICs of either free Oﬂx or Oﬂx attached onto
nanocarriers for WT-BmrA and ΔBmrA cells are the same,
suggesting that either form of Oﬂx could be extruded out of the
cells by other membrane transporters in both WT-BmrA and
ΔBmrA. In other words, Oﬂx is not a speciﬁc substrate of

Control experiments (Figure 6: a−c) show that the
OD600 nm of the cell suspension incubated with each of three
diﬀerent sized AgMUNH2 NPs (absence of Oﬂx) are nearly
independent on the NP concentration and nearly the same as
those cultured in the medium alone. The result indicates that
the given concentration of AgMUNH2 NPs does not generate
signiﬁcant inhibitory eﬀects against the growth of WT and
ΔBmrA cells. Note that the NP concentration is the same as
that of the highest concentration of the given sized
nanocarriers, respectively. The studies have shown that the
bare noble metal NPs (Ag NPs) themselves can inhibit the
growth of bacteria in a concentration-dependent manner.32,59,60 Notably, the NPs that are functionalized with the
surface molecules (e.g., peptides) exhibit biocompatibility of
1629
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create the highest inhibitory eﬀects, while the smallest
nanocarriers generate the lowest inhibitory eﬀects, demonstrating that the same number of antibiotic molecules (Oﬂx) that
are carried and delivered by the larger NPs can produce the
higher inhibitory eﬀects. These results indicate that the closedpacked Oﬂx molecules on the surface of NPs might strengthen
their binding aﬃnity with the target (multivalence) and
provide larger payload to increase local targeting dose, leading
to the higher potency. (ii) The inhibitory eﬀects of Oﬂx
depend upon the multivalent local targeting eﬀects, as well as
their intracellular distribution and concentrations. (iii) Their
inhibitory eﬀects do not signiﬁcantly depend upon the cellular
expression of multidrug BmrA membrane transporter,
suggesting that other transporters in ΔBmrA could eﬀectively
extrude the antibiotic nanocarriers out of the ΔBmrA cells,
leading to the same MICs as WT-BmrA. These ﬁndings show
that the inhibitory eﬀects of nanocarriers are not linearly
proportional to their sizes, suggesting the possibility for one to
design the optimal-sized nanocarriers to create the most potent
eﬀect of antibiotics against a speciﬁc given bacterial strain and
to potentially evade a speciﬁc given multidrug membrane
transporter. Eﬀorts are being made to identify the speciﬁc
membrane transporters that are responsible for the extrusion of
drug nanocarriers out of WT-BmrA and ΔBmrA cells and to
study their underlying molecular mechanisms.

BmrA, and other membrane transporters are primary forces to
extrude the Oﬂx out of the cells, which leads to the
insigniﬁcant (or masked) contribution of BmrA and the
BmrA-independent MICs of Oﬂx.
Comparison of Both Studies and Distinctive Findings. By comparing the results in this study with our previous
study,30 we found that Oﬂx attached onto the nanocarriers
retains its eﬃcacy (inhibitory eﬀect) against both Grampositive bacteria (B. subtilis) and Gram-negative bacteria (P.
aeruginosa). Inhibitory eﬀects of nanocarriers against both
strains of bacteria highly depend upon the size of nanocarriers,
further demonstrating that the closed-packed Oﬂx molecules
on the NPs (multivalence) could increase local drug dose,
enhance their binding aﬃnity with the target, and oﬀer higher
potency against both B. subtilis and P. aeruginosa. Notably, the
inhibitory eﬀects of nanocarriers are not linearly proportional
to their sizes. For example, the smallest antibiotic nanocarriers
(2.4 ± 0.7 nm) show the lowest inhibitory eﬀects and the
highest MICs against both strains than free Oﬂx, while the
mid-sized nanocarriers (13.0 ± 3.1 nm) display the nearly
identical inhibitory eﬀects and MICs as free Oﬂx, and the
largest antibiotic nanocarriers (92.6 ± 4.4 nm) exhibit the
highest inhibitory eﬀects and the lowest MICs against both
strains.
The primary diﬀerence between both studies is their
inhibitory eﬀects on two diﬀerent types of the cells (B. subtilis
and P. aeruginosa) and their dependence on the eﬄux pump.
For the previous study,30 the inhibitory eﬀects of nanocarriers
highly depend upon the expression of MexAB-OprM (multidrug membrane transporter) of P. aeruginosa (Gram-negative
bacterium). In this study, they are independent upon the
expression of BmrA (multidrug membrane transporter) of B.
subtilis (Gram-positive bacterium). Therefore, the inhibitory
eﬀects of nanocarriers against bacteria show the selectivity,
suggesting the possibility of using them as medicines. Notably,
all three sized nanocarriers can enter B. subtilis (Gram-positive
bacteria) and P. aeruginosa(Gram-negative bacteria), even
though B. subtilis (Gram-positive bacteria) possess a very
diﬀerent envelop structure from P. aeruginosa (Gram-negative
bacteria), suggesting potential common applications against
bacteria. Further, the results demonstrate that antibiotic drug
nanocarriers show speciﬁcity toward the given membrane
transporters and their potentially wide utility against both
Gram-positive and Gram-negative bacteria.

■

MATERIALS AND METHODS
Characterization of Cell Culture. We used two strains of
Gram-positive bacterial cells (B. subtilis): WT (normal
expression BmrA) and ΔBmrA previously named as ΔYvcC
(a mutant strain that is devoid of the bmrA, also named as
ΔyvcC or ΔbmrA) that were isogenic strains and provided by
Jault.26 The cells were ﬁrst precultured in a commonly used
standard LB medium (1% tryptone, 0.5% yeast extract, and
0.5% NaCl in DI water, pH = 7.2) in a shaker (MaxQ 5000,
200 rpm, 37 °C) for 12 h. The precultured cells (20 μL) were
then further cultured in the 2 mL standard LB medium or the
modiﬁed LB medium (1% tryptone, 0.5% yeast extract, and
0.1% NaCl in DI water, pH = 7.2) in a shaker (MaxQ 5000,
200 rpm, 37 °C) for another 17 h. The cell growth curves were
determined by measuring the OD600 nm of cell suspension in
the medium over 17 h of cell culture. The cell suspension was
diluted to the OD600 nm of cell suspension below 0.2 and
measured.
By the end of cell culture, we used live/dead BacLight
viability and counting assay (Invitrogen) to assay the viability
of the cultured cells.52 We used dark-ﬁeld optical microscopy
and epi-ﬂuorescence microscopy to image the cells in a
microchamber containing the medium.33,37,39,40,53 We acquired
the green and red ﬂuorescence cell images and counted them
as live and dead cells, respectively.
By the end of the cell culture, we used centrifugation to
harvest the cells (Beckman JA-14, 7500 rpm) and rinsed the
cells with the PBS buﬀer (0.5 mM phosphate buﬀer, 1.5 mM
NaCl, pH 7.0) three times. We suspended the cells in the PBS
buﬀer and adjusted to a desired cell suspension concentration
(OD600 nm = 0.1) in the buﬀer. We continuously measured the
ﬂuorescence intensity of Hoechst 3342 dye (Invitrogen) of the
cell suspension (OD600 nm = 0.1) containing 2 μM of the dye at
a 3 s time interval for 2 h using a ﬂuorescence spectrometer
(PerkinElmer LS50B) with the excitation and emission
wavelengths at 350 and 488 nm, respectively.

■

SUMMARY
In summary, we have successfully used three diﬀerent sized
antibiotic drug nanocarriers (AgMUNH−Oﬂx NPs) to study
their size-dependent inhibitory eﬀects against Gram-positive
bacteria (Bacillus subtilis, WT-BmrA, and ΔBmrA). We have
designed a modiﬁed cell culture medium, which enables the
WT-BmrA and ΔBmrA cells to grow normally and the
antibiotic drug nanocarriers to be stable (nonaggregated) in
the medium over the entire duration of cell culture (17 h).
Thus, the size and dose of nanocarriers remain unchanged
during their incubation with the cells for 17 h, enabling us to
study the size- and dose-dependent eﬀects of the drug
nanocarriers on the cell growth and eﬄux function of BmrA.
Control experiments of three sized AgMUNH2 NPs (absence
of Oﬂx) show insigniﬁcant inhibitory eﬀects toward WT-BmrA
and ΔBmrA, which are likely attributed to the surface
functional molecules (MUNH2) attached onto the NPs. The
signiﬁcant ﬁndings include that (i) the largest nanocarriers
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conjugation ratio of 8.6 × 102 Oﬂx molecules per NP; (ii) 5.8
× 10−3, 1.2 × 10−2, 2.3 × 10−2, 4.6 × 10−2, and 7.6 × 10−2 nM
for (13.0 ± 3.1) nm NPs with a conjugation ratio of 9.4 × 103
Oﬂx molecules per NP; and (iii) 8.4 × 10−2, 1.7 × 10−1, 3.4 ×
10−1, 6.4 × 10−1, and 1.11 pM for (92.6 ± 4.4) nm NPs with a
conjugation ratio of 6.5 × 105 Oﬂx molecules per NP. The
control experiments include the modiﬁed LB medium only
(blank control) and containing 0.83 nM, 7.6 × 10−2 nM, or 1.1
pM AgMUNH2 NPs (in the absence of Oﬂx) for 2.4 ± 0.7,
13.0 ± 3.1, or 92.6 ± 4.4 nm NPs, respectively.
We quantitatively determined the OD600 nm of the cell
suspension in a 96-well plate using a plate reader (BioTek
Synergy HT) equipped with a UV−vis absorption spectral
detector at 5, 11, and 17 h. We plotted the OD600 nm of the cell
suspension vs time to determine the duration (17 h) for the
cells to reach the conﬂuence. We then used the plots of the
OD600 nm of each cell suspension at 17 h versus Oﬂx
concentration (free Oﬂx or Oﬂx attached onto the nanocarrier)
to determine their inhibitory eﬀects (MIC). Speciﬁcally, we
normalized the OD600 nm of each cell suspension with the
maximum OD600 nm (the cells cultured in the medium alone,
blank control), respectively. We plotted the normalized
OD600 nm of the cell suspension versus the concentration of
free Oﬂx (Oﬂx alone) or the concentration of Oﬂx attached
onto a given sized drug nanocarrier. We used the exponential
decay (y = a e−bx) to ﬁt the experimental data and to determine
the parameters (a, b) of the equation with the highest possible
regression. The MIC50 (the concentration of Oﬂx at which the
cell growth was inhibited to the half of the cell growth of the
blank control experiment) was then determined. Unlike
conventional semiquantitative methods to estimate the MICs
using solid culture plates (a colony-forming unit), we
developed this new approach to quantitatively determine the
MIC50 using the dilution series of antibiotics or antibiotic
nanocarriers in the liquid LB medium and mathematically
ﬁtting the experimental data. Further, the dilution series of
antibiotics in the liquid LB medium enabled the nanocarriers
to be well dispersed and avoided the aggregation of
nanocarriers in the solid culture plates and allowed us to
characterize the stability of nanocarriers in the liquid medium
in real time at single NP resolution.

Synthesis, Puriﬁcation, and Characterization of Drug
Nanocarriers. We synthesized and characterized the antibiotic drug nanocarriers, as reported previously.30 Brieﬂy, we
synthesized, puriﬁed, and characterized (2.4 ± 0.7), (13.0 ±
3.1), and (92.6 ± 4.4) nm Ag NPs, as reported
previously.39,42,62 We used centrifugation to thoroughly wash
the NPs three times with the DI water immediately after the
synthesis. We used UV−vis spectroscopy (Hitachi U-2010),
dark-ﬁeld optical microscopy and spectroscopy (DFOMS),
high-resolution transmission electron microscopy (JEOL, JEM2100F), and dynamic light scattering (DLS) (Nicomp 380ZLS
particle sizing system) to measure the NP concentrations, the
LSPR images, the spectra of single NPs, and the sizes of single
NPs, respectively.33,36,37,39,42−45,47,49,55,62 We used the interaction of thiol groups of MUNH2 with the NPs to attach 11amino-1-undecanethiol hydrochloride (MUNH2, AUT, 99%,
Sigma-Aldrich) onto the surface of NPs to prepare functional
AgMUNH2 NPs. We used centrifugation (Beckman Optima
L90k, 4 °C) to wash the AgMUNH2 NPs thoroughly with DI
water three times to remove excess MUNH2. We used a twostep method via 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide
(s-NHS) as mediators to link the amine groups of each sized
AgMUNH2 NPs with the carboxyl group of Oﬂx via peptide
bonds (Figure 1). We used centrifugation to wash the
nanocarriers with DI water to purify the drug nanocarriers
(AgMUNH−Oﬂx NPs) and stored them at 4°C for future use.
We used UV−vis spectroscopy, DFOMS, and DLS to
characterize the concentrations, optical properties, and sizes
of each sized AgMUNH2 NPs, respectively.
We used UV−vis absorbance spectra of Oﬂx at 288 nm and
the plasmonic absorption spectra of the NPs to measure the
molar concentration of Oﬂx and NPs, respectively. We then
divided the molar concentrations of Oﬂx molecules on the
surface of the nanocarriers by the molar concentration of the
NPs to determine the molar labeling ratios of antibiotics (Oﬂx)
to NPs for each sized drug nanocarriers.30
Study of Stability of Drug Nanocarriers in Cell
Culture Medium. We used UV−vis absorption spectroscopy,
DLS, and dark-ﬁeld optical microscopy and spectroscopy to
characterize the concentration, size, and optical properties of
nanocarriers and studied their stability (nonaggregation) in the
commonly used standard LB medium and the modiﬁed
medium over 24 h, respectively. We found that the given
concentrations of 2.4 ± 0.7, 13.0 ± 3.1, and 92.6 ± 4.4 nm
nanocarriers (6.0 nM, 0.8 nM, and 7 pM) are stable
(nonaggregated) in the modiﬁed medium over 24 h, but
they are unstable (aggregated) in the standard medium.30
Characterization of Dose- and Size-Dependent
Inhibitory Eﬀects of Nanocarriers. The cells (WT or
ΔBmrA) were precultured in the standard LB medium
overnight and then cultured in the modiﬁed LB medium
(2.5 mL) containing a dilution series of free Oﬂx alone, given
sized drug nanocarriers (AgMUNH−Oﬂx NPs), and AgMUNH2 NPs (control experiments) by inoculating 104
precultured cells into the medium in a shaker (200 rpm, 37
°C) over 17 h.
The dilution series of 0, 0.055, 0.11, 0.22, 0.42, and 0.72 μM
free Oﬂx or Oﬂx conjugated with the NPs (AgMUNH−Oﬂx
NPs) were prepared in the modiﬁed cell culture medium to
culture WT and ΔBmrA (Figure 5). They are correlated with
the drug nanocarrier (NP) concentrations: (i) 0, 0.06, 0.13,
0.26, 0.49, and 0.83 nM for (2.4 ± 0.7) nm NPs with a
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Growth curve of WT-BmrA cells incubated with (A) free
Oﬂx, (B) 2.4 ± 0.7, (C) 13.0 ± 3.1, and (D) 92.6 ± 4.4
nm Oﬂx nanocarriers, and AgMUNH2 NPs (in the
absence of Oﬂx, control experiment) (Figure S1); and
growth curve of ΔBmrA cells incubated with (A) free
Oﬂx, (B) 2.4 ± 0.7, (C) 13.0 ± 3.1, and (D) 92.6 ± 4.4
nm Oﬂx nanocarriers, and AgMUNH2 NPs (in the
absence of Oﬂx, control experiment) (Figure S2) (PDF)
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